<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Women's Health - Latest articles</title>
		<link>http://www.biomedcentral.com/bmcwomenshealth/</link>
		<description>The latest articles from BMC Women's Health (ISSN 1472-6874) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/11"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/10"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/9"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/6"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/4"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/8/2"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/11">
            
            <title>The ESEP study: salpingostomy versus salpingectomy for tubal ectopic pregnancy; the impact on future fertility: a randomised controlled trial ISRCTN37002267</title>
			<description>Background:
For most tubal ectopic pregnancies (EP) surgery is the treatment of first choice. Whether surgical treatment should be performed conservatively (salpingostomy) or radically (salpingectomy) in women wishing to preserve their reproductive capacity, is subject to debate. Salpingostomy preserves the tube, but bears the risks of both persistent trophoblast and repeat ipsilateral tubal EP. Salpingectomy, avoids these risks, but leaves only one tube for reproductive capacity. This study aims to reveal the trade-off between both surgical options:
whether the potential advantage of salpingostomy, i.e. a better fertility prognosis as compared to salpingectomy, outweighs the potential disadvantages, i.e. persistent trophoblast and an increased risk for a repeat EP.
Methods:
International multi centre randomised controlled trial comparing salpingostomy versus salpingectomy in women with a tubal EP without contra lateral tubal pathology. Hemodynamically stable women with a presumptive diagnosis of tubal EP, scheduled for surgery, are eligible for inclusion. Patients pregnant after in vitro fertilisation (IVF) and/or known documented tubal pathology are excluded. At
surgery, a tubal EP must be confirmed. Only women with a tubal EP amenable to both interventions and a healthy contra lateral tube are included. Salpingostomy and salpingectomy are performed according to standard procedures of participating hospitals. Up to 36 months after surgery, women will be contacted to assess their fertility status at six months intervals starting form the day of the operation.
The primary outcome measure is the occurrence of spontaneous viable intra uterine pregnancy. Secondary outcome measures are persistent trophoblast, repeat EP, all pregnancies including those resulting from IVF and financial costs. The analysis will be performed according to the intention to treat principle. A cost-effectiveness analysis will be performed within a decision analysis framework, based on costs per live birth, including IVF treatment whenever a spontaneous pregnancy does not occur. Patients' preferences will be assessed using a discrete choice experiment.DiscussionThis trial will provide evidence on the trade off between salpingostomy and salpingectomy for tubal EP in view of the pros and cons of both interventions and will offer guidance to clinicians in making the right treatment choice. Trial registration: Current Controlled Trials ISRCTN37002267</description>
			<link>http://www.biomedcentral.com/1472-6874/8/11</link>
			
			 	<dc:creator>Femke Mol, Annika Strandell, Davor Jurkovic, Tamer Yalcinkaya, Harold R Verhoeve, Carolien AM Koks, Paul JQ van der Linden, Giuseppe CM Graziosi, Andreas L Thurkow, Annemieke Hoek, Lars Hogstrom, Ingemar Klinte, Kerstin Nilsson, Norah M van Mello, Willem M Ankum, Fulco van der Veen, Ben WM Mol and Petra J Hajenius</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:11</dc:source>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-11</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/10">
            
            <title>The METEX study: methotrexate versus expectant management in women with ectopic pregnancy: a randomised controlled trial.</title>
			<description>Background:
Patients with ectopic pregnancy (EP) and low serum hCG concentrations and women with a pregnancy of unknown location (PUL) and plateauing serum hCG levels are commonly treated with systemic methotrexate (MTX). However, there is no evidence that treatment in these particular subgroups of women is necessary as many of these early EPs may resolve spontaneously. The aim of this study is whether expectant management in women with EP or PUL and with low but plateauing serum hCG concentrations is an alternative to MTX treatment in terms of treatment success, future pregnancy, health related quality of life and costs. 
Methods:
A multicentre randomised controlled trial in The Netherlands. Hemodynamically stable patients with an EP visible on transvaginal ultrasound and a plateauing serum hCG concentration &lt; 1,500 IU/L or with a persisting PUL with plateauing serum hCG concentrations &lt; 2,000 IU/L are eligible for the trial. Patients with a viable EP, signs of tubal rupture/abdominal bleeding, or a contra-indication for MTX will not be included. Expectant management is compared with systemic MTX in a single dose intramuscular regimen (1 mg/kg) in an outpatient setting. Serum hCG levels are monitored weekly; in case of inadequately declining, systemic MTX is installed or continued. In case of hemodynamic instability and/or signs of tubal rupture, surgery is performed. The primary outcome measure is an uneventful decline of serum hCG to an undetectable level by the initial intervention. Secondary outcomes are (re)interventions (additional systemic MTX injections and/or surgery), treatment complications, health related quality of life, financial costs, and future fertility. Analysis is performed according to the intention to treat principle. Quality of life is assessed by questionnaires before and at three time points after randomisation. Costs are expressed as direct costs with data on costs and used resources in the participating centres. Fertility is assessed by questionnaires after 6, 12, 18 and 24 months. Patients' preferences will be assessed using a discrete choice experiment.DiscussionThis trial will provide guidance on the present management dilemmas in women with EPs and PULs with low and plateauing serum hCG concentrations. Trial registration: Current Controlled Trials ISRCTN 48210491</description>
			<link>http://www.biomedcentral.com/1472-6874/8/10</link>
			
			 	<dc:creator>Norah M van Mello, Femke Mol, Albert H Adriaanse, Erik A Boss, Antonius B Dijkman, Johannes PR Doornbos, Mark Hans Emanuel, Jaap Friederich, Loes van der Leeuw-Harmsen, Jos P Lips, Evert JP van Santbrink, Harold R Verhoeve, Harry Visser, Willem M Ankum, Fulco van der Veen, Ben WM Mol and Petra J Hajenius</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:10</dc:source>
			<dc:date>2008-06-19</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-10</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/9">
            
            <title>Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women</title>
			<description>Background:
This study was conducted to determine whether use of hormonal contraceptives is associated with cervical dysplasia and cancer in a population where there is widespread use of hormonal contraception and the rates of cervical cancer remain high at 27.5/100,000.
Methods:
A case-control study was conducted among women visiting the colposcopy and gynaelogical clinics at a tertiary referral hospital. Two hundred and thirty six cases CIN I (72), II (59), III (54), cancer (51) and 102 controls, consented and were interviewed on use of contraceptives using a structured questionnaire. Logistic regression was used to determine odds ratios (ORs) and 95% confidence intervals (CIs) associated with use of hormonal contraception in cases and controls and in low and high risk cases. Recruitment was carried out from 2001&#8211;2002.
Results:
Contraceptives used were: oral contraceptives &#8211; 35%, injections (depot medroxy progesterone acetate (Depo-provera) &#8211; 10%, Intrauterine devices &#8211; 2%, combinations of these and tubal ligation &#8211; 30%. 23% reported use of 'other' methods, barrier contraceptives or no form of contraception. Barrier contraceptive use was not significantly different between cases and controls. Current and/or past exposure to hormonal contraceptives (HC) by use of the pill or injection, alone or in combination with other methods was significantly higher in the cases. In multivariate analysis with age and number of sexual partners as co-variates, use of hormonal contraception was associated both with disease, [OR, 1.92 (CI 1.11, 3.34; p = 0.02] and severity of the disease [OR, 2.22 (CI 1.05, 4.66) p = 0.036]. When parity and alcohol consumption were added to the model, hormonal contraception was no longer significant. The significant association with high risk disease was retained when the model was controlled for age and number of sexual partners. Depo-provera use (with age and number of sexual partners as covariates) was also associated with disease [OR, 2.43 (CI 1.39, 4.57), p = 0.006] and severity of disease [OR 2.51 (1.11, 5.64) p = 0.027]. With parity and alcohol added to this model, depo-provera use retained significance. Exposure to HC > 4 years conferred more risk for disease and severity of disease.
Conclusion:
Hormonal contraception did confer some risk of dysplasia and women using HC should therefore be encouraged to do regular Pap smear screening.</description>
			<link>http://www.biomedcentral.com/1472-6874/8/9</link>
			
			 	<dc:creator>Norma McFarlane-Anderson, Patience E Bazuaye, Maria D Jackson, Monica Smikle and Horace M Fletcher</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:9</dc:source>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-9</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/8">
            
            <title>A systematic review of tests for lymph node status in primary endometrial cancer</title>
			<description>Background:
The lymph node status of a patient is a key determinate in staging, prognosis and adjuvant treatment of endometrial cancer. Despite this, the potential additional morbidity associated with lymphadenectomy makes its role controversial. This study systematically reviews the accuracy literature on sentinel node biopsy; ultra sound scanning, magnetic resonance imaging (MRI) and computer tomography (CT) for determining lymph node status in endometrial cancer.
Methods:
Relevant articles were identified form MEDLINE (1966&#8211;2006), EMBASE (1980&#8211;2006), MEDION, the Cochrane library, hand searching of reference lists from primary articles and reviews, conference abstracts and contact with experts in the field. The review included 18 relevant primary studies (693 women). Data was extracted for study characteristics and quality. Bivariate random-effect model meta-analysis was used to estimate diagnostic accuracy of the various index tests.
Results:
MRI (pooled positive LR 26.7, 95% CI 10.6 &#8211; 67.6 and negative LR 0.29 95% CI 0.17 &#8211; 0.49) and successful sentinel node biopsy (pooled positive LR 18.9 95% CI 6.7 &#8211; 53.2 and negative LR 0.22, 95% CI 0.1 &#8211; 0.48) were the most accurate tests. CT was not as accurate a test (pooled positive LR 3.8, 95% CI 2.0 &#8211; 7.3 and negative LR of 0.62, 95% CI 0.45 &#8211; 0.86. There was only one study that reported the use of ultrasound scanning.
Conclusion:
MRI and sentinel node biopsy have shown similar diagnostic accuracy in confirming lymph node status among women with primary endometrial cancer than CT scanning, although the comparisons made are indirect and hence subject to bias. MRI should be used in preference, in light of the ASTEC trial, because of its non invasive nature.</description>
			<link>http://www.biomedcentral.com/1472-6874/8/8</link>
			
			 	<dc:creator>Tara J Selman, Christopher H Mann, Javier Zamora and Khalid S Khan</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:8</dc:source>
			<dc:date>2008-05-05</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-05</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/7">
            
            <title>Abnormal vaginal bleeding in women of reproductive age: a descriptive study of initial management in general practice</title>
			<description>Background:
Abnormal vaginal bleeding (AVB) in women of reproductive age is a common reason for consulting a general practitioner. Nevertheless, how general practitioners (GPs) choose to initially manage AVB is largely unknown, as is the prevalence of underlying pathology of AVB in primary care.
Methods:
To investigate the initial diagnostic procedures and treatment for AVB used in general practice, we performed a descriptive study based on computerised medical records. New consultations for AVB in 2000 and 2001 were selected. Patient characteristics, diagnostic procedures and treatment were analysed.
Results:
In total, 270 new consultations were included. The majority of patients (75%) consulted the GP for AVB only once. GPs performed diagnostic procedures in 54% of all consultations. Overall, additional diagnostic procedures revealed abnormalities in 11% of women. However, the diagnostic procedures implemented by the GPs varied widely per bleeding type and contraceptive use. Anaemia was found in 36% of 45 women tested. Uterine fibroids were found in 41% of 27 women examined by ultrasound. Medication was prescribed in 34% of all consultations. A gynaecological referral was registered in 4% of all contacts.
Conclusion:
Initially, GPs tend to follow a policy of expectant management in women of reproductive age with AVB. However, when additional diagnostic procedures were performed, anaemia and uterine fibroids were found in a considerable number of women.</description>
			<link>http://www.biomedcentral.com/1472-6874/8/7</link>
			
			 	<dc:creator>Corlien JH de Vries, Margreet Wieringa-de Waard, Cl&#233;o-Lotte AG Vervoort, Willem M Ankum and Patrick JE Bindels</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:7</dc:source>
			<dc:date>2008-04-15</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/6">
            
            <title>Variation in NHS utilisation of vault smear tests in women post-hysterectomy: A study, using routinely collected datasets</title>
			<description>Background:
20% of women living in the UK have a hysterectomy during their lifetime, levels are higher in the USA, making it one of the most commonly performed major surgical procedures. Understanding of the indications for hysterectomy and of the rationale for follow-up of women post hysterectomy is currently limited. Guidelines concerning follow-up by means of vaginal vault cytology tests exist but these are not based on 'gold standard' evidence. Furthermore, the extent to which current practice reflects these guidelines is unclear. This study aims to determine the factors associated with variability in hysterectomy rates and subsequent follow-up after surgery by use of the vaginal vault smear cytology test.Methods/DesignAll women resident in the West Midlands region, of the United Kingdom, who had a hysterectomy operation between 1st April 2002 and 30th March 2003 will be identified from the Hospital Episodes Statistics database which also contains proxy data on deprivation status, derived from postcode and self declared ethnicity. These data will be linked to regional cervical screening records for each woman and histopathology laboratory records from the relevant hospitals. Study objectives are to describe: Indications for the hysterectomy operation, histology at hysterectomy, subsequent follow-up by use or non-use of vaginal vault cytology tests and variation between histological groups. Additionally the data will be categorised according to a woman's cytology screening history prior to surgery (i.e. always normal, borderline, resolved abnormalities, CIN etc) and these different groups compared. Variations in these outcomes according to age, deprivation and ethnic group will also be examined. Analysis will be undertaken using SPSS.DiscussionThis study will clarify patterns of current practice in one large English region and determine whether this practice reflects existing guidelines. The study will also strengthen the evidence base for future guidelines.Study registrationNational Research Register N0138173331</description>
			<link>http://www.biomedcentral.com/1472-6874/8/6</link>
			
			 	<dc:creator>Helen J Stokes-Lampard, John Macleod and Sue Wilson</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:6</dc:source>
			<dc:date>2008-03-28</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-6</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/5">
            
            <title>Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial</title>
			<description>Background:
The aim of the study was to determine the effect of postmenopausal hormone therapy on women's symptom reporting and quality of life in a randomized trial.
Methods:
1823 women participated in the Estonian Postmenopausal Hormone Therapy (EPHT) Trial between 1999 and 2004. Women were randomized to open-label continuous combined hormone therapy or no treatment, or to blind hormone therapy or placebo. The average follow-up period was 3.6 years. Prevalence of symptoms and quality of life according to EQ-5D were assessed by annually mailed questionnaires.
Results:
In the hormone therapy arms, less women reported hot flushes (OR 0.20; 95% CI: 0.14&#8211;0.28), sweating (OR 0.56; 95% CI: 0.44&#8211;0.72), and sleeping problems (OR 0.66; 95% CI: 0.52&#8211;0.84), but more women reported episodes of vaginal bleeding (OR 19.65; 95% CI: 12.15&#8211;31.79). There was no difference between the trial arms in the prevalence of other symptoms over time. Quality of life did not depend on hormone therapy use.
Conclusion:
Postmenopausal hormone therapy decreased vasomotor symptoms and sleeping problems, but increased episodes of vaginal bleeding, and had no effect on quality of life.Trial registration numberISRCTN35338757</description>
			<link>http://www.biomedcentral.com/1472-6874/8/5</link>
			
			 	<dc:creator>Piret Veerus, Krista Fischer, Sirpa-Liisa Hovi, Helle Karro, Mati Rahu and Elina Hemminki</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:5</dc:source>
			<dc:date>2008-03-26</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/4">
            
            <title>How does social integration influence breast cancer control among urban African-American women? Results from a cross-sectional survey</title>
			<description>Background:
Although social integration is a well-established influence on health, less is known about how the specific types of social connection (social roles, social networks, and social support) influence knowledge, attitudes, and practices for specific prevention goals, and how to utilize these influences in interventions with priority populations. This research examined the prevalence of social roles, networks and support among 576 urban African-American women age 45&#8211;93 in East Baltimore, Maryland, and the association of these social factors with breast cancer related knowledge, attitudes, and practices.
Methods:
Using data from 1997&#8211;1998 in-home interviews, we developed indices of six possible social roles, social networks of family, neighborhood and church, and instrumental and emotional social support. In multivariate models adjusting for age, education, and medical care, we examined the association of each social influence on breast cancer knowledge, attitudes, screening recency and intention, and treatment preferences.
Results:
We found substantial variation in social integration among these women, with social integration positively associated with overall health and well-being. Social roles and networks were positively associated with screening knowledge, and emotional support and church networks were positively associated with attitudes conducive to early detection and treatment. In regard to screening behaviors, family networks were associated with both screening recency and intention. Women with greater church networks and emotional support held more conservative attitudes towards lumpectomy, reconstruction, and clinical trials.
Conclusion:
Overall, social integration is a positive influence on breast cancer control and should be utilized where possible in interventions, including identifying surrogate mechanisms for support for subgroups without existing social resources.</description>
			<link>http://www.biomedcentral.com/1472-6874/8/4</link>
			
			 	<dc:creator>Ann Carroll Klassen and Carmen Washington</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:4</dc:source>
			<dc:date>2008-02-06</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/3">
            
            <title>Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study</title>
			<description>Background:
The primary objective of this study was to investigate if supplementary lactobacilli treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial cure.
Methods:
Women (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109 freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-blind, randomized, placebo-controlled trial.
Results:
The initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears at the initial visit who continued the study and whose next smear indicated a cure was included in the cured group; the study also excluded two of the patients in the lactobacilli group who reported that they did not take any vaginal capsules. With consideration to these population changes, the initial cure rate would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse with a proportional Hazard Risk ratio (HR) of 0.73 (0.54&#8211;0.98) (p &lt; 0.05)
Conclusion:
The study shows that supplementary treatment combining two different strains of probiotic lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse significantly in that more women remained BV free at the end of the 6-month follow up.Trial registration numberISRCTN62879834</description>
			<link>http://www.biomedcentral.com/1472-6874/8/3</link>
			
			 	<dc:creator>Per-G&#246;ran Larsson, Babill Stray-Pedersen, Kjeld R Ryttig and Stig Larsen</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:3</dc:source>
			<dc:date>2008-01-15</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6874/8/2">
            
            <title>Women's colposcopy experience and preferences: a mixed methods study</title>
			<description>Background:
The colposcopy service is a key component in the UK Cervical Screening Programme. Over 120,000 women are referred to the service annually, however up to 25% of women fail to attend their appointment. Little is known about patients' preferences for colposcopic investigation and treatment. This study aims to investigate women's experience of colposcopy, to identify patients' preferences for aspects of appointments within the colposcopy service, and to make suggestions for service improvement.Methods/DesignThis study has been designed as a two stage, mixed method project. Stage one will involve in-depth interviews with new colposcopy patients to ascertain their experience of colposcopy services. This qualitative stage will generate factors thought to be important by service users in their experience. Stage two will utilise a choice based quantitative technique to identify women's preferences and determine the representativeness of factors generated through the interviews.The initial stage of in-depth interviews will be conducted with patients who are newly referred to colposcopy clinics to investigate the experience that they have of the referral process and appointment attendance. The outcome of these interviews will be analysed qualitatively using Framework analysis. Factors found to be important in women's experience will be extracted and used to construct a choice based questionnaire.The discrete choice experiment (questionnaire) will apply a best-worst technique through scenario-based questions to find women's relative preferences for different aspects of the service. It will be offered to women attending follow-up appointments at two colposcopy clinics in the West Midlands. Women will complete the questionnaire whilst they wait for their appointment, or, if they prefer, will take it home to complete in private. Women who do not attend their appointment will be posted the research information and questionnaire. The questionnaire analysis will use a weighted least squares regression technique for each best/worst pair. The accept/reject 'would you attend this appointment' question will be analysed using a random effects logit model.DiscussionColposcopy is a common procedure and one that is associated with raised anxiety among women experiencing the service. Little is known about women's experience of the service or their preferences for service delivery. The outcomes of the study will comprise a description of women's experience of colposcopy and establishing their preferences for how aspects of the service should be provided. Women's preferences will be fed back to service providers to enable improvements to the service to be made.</description>
			<link>http://www.biomedcentral.com/1472-6874/8/2</link>
			
			 	<dc:creator>Dawn R Swancutt, Sheila M Greenfield and Sue Wilson</dc:creator>
			
			<dc:source>BMC Women's Health 2008, 8:2</dc:source>
			<dc:date>2008-01-14</dc:date>
			<dc:identifier>doi:10.1186/1472-6874-8-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Women's Health</prism:publicationName>
					
			
							
					<prism:issn>1472-6874</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
